Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative ...

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

Diversified Trust Co lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 17.7% in the first quarter, according to its most recent filing with the Securities ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Prosper Junior Bakiny (Vertex Pharmaceuticals): Over the past decade, Vertex Pharmaceuticals, a leading biotech, has generated excellent financial results and market-beating returns, thanks to its ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.

No action by the Company's stockholders is required with respect to the ticker symbol change. The Company's common stock will continue to be listed on Nasdaq and the CUSIP number will remain ...